Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

COVID-19 vaccine-related radiotracer uptake an ‘emerging dilemma’ on PET/CT exams

To avoid misinterpreting imaging findings, UMass Medical School experts suggest scheduling such exams 4-6 weeks after vaccination, when possible.

Thumbnail

FDA-approved PET imaging agent predicts breast cancer patients’ response to new treatment

Oncology experts with the University of Washington in Seattle’s Cancer Research Center shared their findings in the Journal of Nuclear Medicine's February issue.

Automated imaging locks in on brain proteins to detect earliest signs of Alzheimer’s disease

By actively tracking amyloid-beta and tau, Massachusetts General Hospital researchers may be able to diagnose the deadly disease earlier. 

New research expands PET imaging time window for patients with rare neuroendocrine tumors

In light of their findings, University of Copenhagen experts also believe 64Cu-labeled PET tracers will become more commonplace for clinical use.

Thumbnail

Amyloid blood testing could cause 50% drop in PET scans required for Alzheimer’s trials

That’s according to a study of more than 400 dementia-free British citizens, shared recently in Brain.

Thumbnail

Pfizer agrees to new PET license, supply deal with cancer imaging firm ImaginAb

As part of the contract, Los Angeles-based ImaginAb will provide Pfizer will its 89Zr CD8 immuno-PET agent, which is used to image CD8 T cells in cancer patients.

Thumbnail

NorthStar’s recent FDA approval enables a fourfold increase in Mo-99 production

This marks the first and only commercial-scale application of concentrated molybdenum-98 technology, the Beloit, Wisconsin-based firm said recently.

Thumbnail

New copper PET tracer one-two punch identifies deadly tumors and boosts survival

“This offers the potential to provide diagnostic imaging using copper-64 to plan individualized treatments with copper-67 agents for a wide range of cancer patients," Australian researchers explained in the Journal of Nuclear Medicine.